PRF Technologies (PRFX) Share-based Compensation (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Share-based Compensation of -$113000.0 for Q2 2024, down 143.3% year-on-year from $261000.0 in Q3 2023, and down 198.26% on a QoQ basis from $115000.0 in Q1 2024.
PRF Technologies (PRFX) Share-based Compensation (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Share-based Compensation for 5 consecutive years, with -$113000.0 the latest figure, recorded in Q2 2024.
- Quarterly Share-based Compensation fell 143.3% year-over-year to -$113000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $365000.0 (down 73.93% YoY) and the FY2025 annual result came in at $447000.0, up 44.19% from the prior year.
- Share-based Compensation retreated to -$113000.0 in Q2 2024 per PRFX's latest filing, from $115000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for PRFX reached as high as $736000.0 in Q4 2022 and fell as low as -$113000.0 in Q2 2024.
- A 5-year average of $169166.7 and a median of $181500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 7566.67% — and 2024, when it tumbled 143.3%.
- Year by year, Share-based Compensation stood at $3000.0 in 2020, then surged by 7566.67% to $230000.0 in 2021, then jumped by 220.0% to $736000.0 in 2022, then sank by 75.41% to $181000.0 in 2023, then sank by 162.43% to -$113000.0 in 2024.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$113000.0, $115000.0, and $181000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Dec 31, 2022 | 736,000.00 |
| Dec 31, 2022 | 736,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Mar 31, 2022 | 210,000.00 |